STADA Arzneimittel AG - M&A Activity 2017

News Details

Ad-hoc | 10 July 2017 09:15

STADA Arzneimittel AG: Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

STADA Arzneimittel AG / Key word(s): Offer

10-Jul-2017 / 09:15 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bad Vilbel, July 10, 2017 – Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, announced today that it has submitted an application to the German Federal Financial Supervisory Authority (BaFin) for an exemption from the one-year exclusion period to submit a renewed voluntary public takeover offer under section 26(2) of the German Securities Acquisition and Takeover Act (WpÜG). STADA Arzneimittel AG has expressed its consent to the exemption from the exclusion period. The Management Board and the Supervisory Board hold the view that consenting to the exemption from the exclusion period is in the best interest of the company and its stakeholders. After having reviewed the parameters of an envisaged renewed voluntary public takeover offer as communicated by Nidda Healthcare Holding AG, the Management Board and the Supervisory Board agree that the renewed offer has been improved compared to the first one with regard to material aspects. This concerns in particular the offer price which will be increased by 0.25 Euro to 66.25 Euro, enhancing the offer’s transaction security, among other things, by lowering the minimum acceptance threshold from initially 75 percent to 63 percent and setting a shorter acceptance period of four weeks.

If the BaFin grants the exemption from the exclusion period upon the application by Nidda Healthcare AG, the acquiring company of Bain Capital and Cinven will then be in a position to make a renewed voluntary public takeover offer to STADA Arzneimittel AG shareholders, without having to adhere to the relevant exclusion period.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /

Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Or visit us on the internet at www.stada.com

10-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language:	English
Company:	STADA Arzneimittel AG
	Stadastraße 2-18
	61118 Bad Vilbel
	Germany
Phone:	+49 (0)6101 603- 113
Fax:	+49 (0)6101 603- 506
E-mail:	[email protected]
Internet:	www.stada.de
ISIN:	DE0007251803, DE0007251845,
WKN:	725180, 725184,
Indices:	MDAX
Listed:	Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange